Key result
In patients treated with VEGFR-TKIs, the frequency of all-grade anorexia symptoms ranged from 14% to 58%, and grade 3 or 4 anorexia ranged from 0% to 6%.
Why the study?
Cancer-related anorexia frequently occurs during VEGFR-TKI therapy and worsens patient outcomes, but diverse and interconnected causes pose challenges for evaluating and implementing effective interventions.
What is the frequency of cancer-related anorexia in patients treated with VEGFR-TKIs, and what are the effective management strategies?
What is the frequency of cancer-related anorexia in patients treated with VEGFR-TKIs, and what are the effective management strategies?
Cancer-related anorexia is highly prevalent (14-58%) in patients treated with VEGFR-TKIs, highlighting the need for multimodal and multidisciplinary management approaches.
Answers are grounded in this paper and cite their sources.
Clinicians should monitor anorexia during VEGFR-TKI therapy; leaves open optimal prevention and management strategies.
Cancer-related anorexia is a common complication and frequently occurs in cancer patients treated with vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs). Anorexia contributes to malnutrition, body weight loss, and cachexia in affected patients. Furthermore, patients who experience anorexia have worse outcomes than those who maintain their appetite, highlighting the importance of managing anorexia and related symptoms. However, as the causes of anorexia are both diverse and interconnected, there have been challenges in evaluating and implementing effective interventions. In this review, we described the contributing factors to cancer-related anorexia and reviewed recent literature for the frequency of anorexia symptoms in patients treated with VEGFR-TKIs. Additionally, we evaluated the evidence for current interventions and the potential benefits of multimodal and multidisciplinary approaches to care. The frequency of anorexia symptoms in patients who received VEGFR-TKIs ranged from 14%-58% for all-grade anorexia and 0%-6% for grade 3 or 4 anorexia. While many of the interventions for cancer-related anorexia have minimal benefit or adverse events, recent advances in our understanding of cancer-related anorexia suggest that multimodal therapy with multidisciplinary care is a promising avenue of investigation. Several studies currently underway are anticipated to further assess the effectiveness of multimodal approaches.
No takes yet. Share an insight, caveat, or question.
Takahashi et al. (2023) conducted a review in Cancer-related anorexia. Vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) was evaluated on Frequency of anorexia symptoms. In patients treated with VEGFR-TKIs, the frequency of all-grade anorexia symptoms ranged from 14% to 58%, and grade 3 or 4 anorexia ranged from 0% to 6%.
Synapse has enriched 10 related papers. Consider them for comparative context: